May 29, 2009 — The US Food and Drug Administration (FDA) has issued a reminder on the risk for serious fungal infections associated with all tumor necrosis factor-alpha (TNF-alpha) inhibitors, ...

WASHINGTON (Reuters) - U.S. health regulators ordered stronger warnings for prescription drugs to treat rheumatoid arthritis, Crohn's disease and other conditions on Thursday after dozens of patients ...

Tumor necrosis factor (TNF)–alpha inhibitors achieve better endoscopic healing than the newer biologic drugs vedolizumab (Entyvio) and ustekinumab (Stelara) in moderate to severe Crohn's disease, a ...

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced Phase ...

MYMD-1 demonstrated favorable safety and tolerability profile across multiple doses, with no clinically relevant adverse events, supporting advancement of the compound for Sarcopenia and Rheumatoid ...

Transformative potential for novel TNF-alpha inhibitor drug: Estimated $40 billion TNF inhibitor market and $50 billion GLP-1 agonist market BALTIMORE--(BUSINESS WIRE)-- TNF Pharmaceuticals, Inc.

LISA‑TRACKER enzyme‑linked immunosorbent assay (ELISA) kits are manufactured by Theradiag and distributed in the UK by Alpha Laboratories. There are 6 LISA‑TRACKER ELISA kits relevant to this ...

Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...

NEW YORK (Reuters Health) - Three available drugs that belong to the newest class of drugs for treating rheumatoid arthritis -- the tumor necrosis factor (TNF)-alpha blockers -- are equally effective ...

HORSHAM, PA and KENILWORTH, NJ, NOVEMBER 6, 2007—Centocor, Inc., Schering-Plough Corporation, and Mitsubishi Tanabe Pharma Corporation announced today that an estimated one million patients have now ...